摘要
目的:探讨凋亡抑制因子(BIRC5)抗体在非小细胞肺癌(NSCLC)患者血浆中的表达及其与预后的关系。方法:选取首次确诊未经治疗的NSCLC患者211例及健康对照者200例,收集血浆样本。基于BIRC5蛋白结构,运用抗原表位预测工具设计、合成2条线性抗原肽,即BIRC5a、BIRC5b,通过自行建立的ELISA法检测血浆BIRC5抗体水平,分析BIRC5抗体表达与NSCLC患者临床病理特征的关系。结合NSCLC患者随访资料,采用Kaplan-Meier生存曲线及COX回归分析法分析BIRC5抗体表达与NSCLC患者预后的关系。结果:NSCLC患者血浆BIRC5a抗体表达水平显著高于正常对照组(1.33±0.53 vs 1.14±0.51,P<0.001),血浆BIRC5b抗体的表达与健康对照组差异无统计学意义(1.03±0.57 vs 0.99±0.58,P>0.05)。NSCLC患者血浆BIRC5a抗体表达与肿瘤分化程度、组织学类型有关(P<0.05),与性别、年龄、吸烟史、肿瘤大小、淋巴结转移等无关(P>0.05)。NSCLC患者血浆BIRC5b抗体的表达与性别、年龄、吸烟史、肿瘤大小、淋巴结转移、TNM分期均无关(P>0.05)。血浆BIRC5b抗体高表达组患者术后生存期(OS)较BIRC5b抗体低表达组患者显著延长(Log Rank检验,χ2=6.7,P=0.01)。多因素分析结果显示BIRC5b抗体表达为NSCLC患者预后的独立保护因素(HR=0.49,P=0.012)。结论:BIRC5b抗体可能抑制NSCLC发生发展,有望成预测NSCLC预后的生物标志物。
Objective:To explore expression of plasma autoantibodies against BIRC5 in patients with non-small cell lung cancer(NSCLC)and its relationship with prognosis.Methods:211 patients who were first diagnosed with NSCLC(without any treatment)and 200 healthy subjects were recruited,and plasma samples were collected.Two linear peptide antigens derived from BIRC5 protein,namely BIRC5a,BIRC5b,were designed using computational epitope prediction software expression.An optimized ELISA method was developed to detect plasma autoantibodies against BIRC5 and relationship between expression of BIRC5 autoantibodies and clinicopathological characteristics of NSCLC patients were further analyzed.Combined with the follow-up data of NSCLC patients,Kaplan-Meier survival analysis and COX regression model were used to analyze correlation between expression levels of BIRC5 autoantibodies and prognosis of NSCLC patients.Results:Expression levels of BIRC5a autoantibodies in plasma of NSCLC patients were significantly higher than that in plasma of healthy subjects(1.33±0.53 vs 1.14±0.51,P<0.001),and expression levels of plasma BIRC5b autoantibodies were not significantly different between patient group and control group(1.03±0.57 vs 0.99±0.58,P<0.05).Expression levels of BIRC5a autoantibodies in plasma of NSCLC patients were correlated with tumor differentiation grade and histological type(P<0.05),but not correlated with gender,age,smoking history,tumor size and lymph node metastasis(P>0.05).Expressions of BIRC5b autoantibodies in plasma of patients with NSCLC were not correlated with gender,age,smoking history,tumor size,lymph node metastasis,and TNM stage(P>0.05).Overall survival(OS)time of patients in high-level BIRC5b autoantibody group was significantly longer than that of patients in low-level group(Log Rank test,χ2=6.7,P=0.01).Multivariate analysis showed that expression of BIRC5b autoantibodies was an independent protective factor for prognosis of NSCLC patients(HR=0.49,P=0.012).Conclusion:BIRC5 autoantibody may inhibit occurrence and development of NSCLC,and it may be used as a biomarker to predict prognosis of NSCLC patients.
作者
赵欢
马小莉
张萱
韩志峰
刘元涛(指导)
ZHAO Huan;MA Xiao-Li;ZHANG Xuan;HAN Zhi-Feng;LIU Yuan-Tao(Department of Endocrinology,Qingdao Municipal Hospital,Qingdao University,Qingdao 266071,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2021年第1期93-97,共5页
Chinese Journal of Immunology
